Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000578901 | SCV000680817 | pathogenic | not provided | 2017-11-10 | criteria provided, single submitter | clinical testing | The W151X variant has been previously reported in the homozygous state in two siblings with progressive microcephaly, seizures, and developmental delay; ITPase activity in erythrocytes of one of the siblings was found to be severely reduced (Kevelam et. al., 2015). The W151X variant is observed in 11/25636 (0.04%) alleles from individuals of Finnish background, in large population cohorts (Lek et al., 2016). This nonsense variant is predicted to cause loss of normal protein function through protein truncation as the last 44 amino acids are lost. Therefore, we interpret W151X as a pathogenic variant. |
Labcorp Genetics |
RCV000640526 | SCV000762118 | pathogenic | Inosine triphosphatase deficiency | 2024-11-05 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Trp151*) in the ITPA gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 44 amino acid(s) of the ITPA protein. This variant is present in population databases (rs200086262, gnomAD 0.04%). This premature translational stop signal has been observed in individuals with ITPA-related conditions (PMID: 26224535, 30856165). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 218089). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts a region of the ITPA protein in which other variant(s) (p.Arg178Cys) have been observed in individuals with ITPA-related conditions (PMID: 26224535). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
OMIM | RCV000202318 | SCV000257321 | pathogenic | Developmental and epileptic encephalopathy, 35 | 2015-10-01 | no assertion criteria provided | literature only |